Acquired hemophilia A: emerging treatment options
Open Access
- 1 May 2015
- journal article
- review article
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 6, 143-150
Abstract
Acquired hemophilia A is a rare autoimmune disorder caused by an autoantibody (inhibitor) to factor VIII (FVIII) that interferes with its coagulant function and predisposes to severe, potentially life-threatening hemorrhage. Disease management focuses on controlling bleeding, primarily with the use of bypassing therapy and recombinant porcine FVIII, and permanently eradicating the autoantibody using various immunosuppressants. Treatment challenges include delayed diagnosis, difficulty achieving hemostasis and durable remissions, and complications associated with the use of hemostatic and immunosuppressive therapy in a primarily older patient population.Keywords
This publication has 47 references indexed in Scilit:
- Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDOBritish Journal of Haematology, 2013
- Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)Blood, 2012
- Acquired Inhibitors of Coagulation Factors: Part I—Acquired Hemophilia ASeminars in Thrombosis and Hemostasis, 2012
- Porcine factor VIIIHaemophilia, 2012
- Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A – a two‐centre experienceHaemophilia, 2012
- Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)Journal of Thrombosis and Haemostasis, 2012
- Consensus recommendations for the diagnosis and treatment of acquired hemophilia ABMC Research Notes, 2010
- Diagnosis and treatment of acquired haemophiliaHaemophilia, 2010
- International recommendations on the diagnosis and treatment of patients with acquired hemophilia AHaematologica, 2009
- Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experienceHaemophilia, 2007